Related Experiment Video
Updated: Jun 10, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Safety evaluation of tirofiban
Marco Valgimigli1, Matteo Tebaldi
1Chair of Cardiology, Cardiovascular Institute, Azienda Opedaliera Universitaria di Ferrara, Arcispedale S. Anna C.so, Giovecca 203, 44100 Ferrara, Italy. valgmrc@unife.it
Expert Opinion on Drug Safety
|July 31, 2010
Summary
Tirofiban effectively inhibits platelet activity in acute coronary syndrome (ACS), improving clinical events with minimal bleeding risk. This potent antiplatelet therapy is safe and superior to placebo, with rare thrombocytopenia.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Heightened platelet activity is central to thrombosis in acute coronary syndrome (ACS).
- Glycoprotein IIb/IIIa inhibitors like tirofiban are crucial for managing ACS.
- Tirofiban demonstrates efficacy and safety, with minor bleeding as the primary adverse event, and rare, reversible thrombocytopenia.
Purpose of the Study:
- To review the rationale for potent antiplatelet therapy in high-risk ACS patients.
- To provide an overview of tirofiban's pharmacology.
- To summarize clinical efficacy and safety data for two tirofiban dosing regimens.
Main Methods:
- Review of clinical trial data on tirofiban in ACS management.
- Analysis of tirofiban's pharmacology and dosing regimens.
- Comparison of tirofiban's efficacy and safety against placebo and abciximab.
Main Results:
- Tirofiban provides potent platelet inhibition.
- Significant improvement in clinical events observed with tirofiban compared to placebo.
- Tirofiban demonstrates comparable efficacy to abciximab with significantly lower rates of thrombocytopenia.
Conclusions:
- Tirofiban is a safe and effective treatment for patients with ACS.
- A single bolus dose regimen is effective when initiated early (first medical contact or pre-PCI).
- Tirofiban offers similar efficacy to abciximab with an improved safety profile regarding thrombocytopenia.
